Pediatric perspective on pharmacogenomics

Pharmacogenomics

Volumn 14, Issue 15, 2013, Pages 1889-1905

  Stevens, Adam ^a   De Leonibus, Chiara ^a   Hanson, Daniel ^a   Whatmore, Andrew ^a   Murray, Philip ^a   Donn, Rachelle ^b   Meyer, Stefan ^c   Chatelain, Pierre ^d   Clayton, Peter ^a  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^b NIHR Biomedical Research Unit   (United Kingdom)

^c Stem Cell and Leukaemia Proteomics Laboratory   (United Kingdom)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Adverse drug reactions; Pediatrics; Personalized medicine; Pharmacogenomics

Indexed keywords

ANTHRACYCLINE; AZATHIOPRINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CISPLATIN; CODEINE; CORTICOSTEROID; FLUTICASONE PROPIONATE; GROWTH HORMONE RECEPTOR; HYDROXYUREA; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MERCAPTOPURINE; METHOTREXATE; PARACETAMOL; RECOMBINANT GROWTH HORMONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ASTHMA; BIRTH DEFECT; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHILD DEVELOPMENT; CLINICAL PRACTICE; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; ENDOCRINOLOGY; GASTROENTEROLOGY; GENE; GENETIC ASSOCIATION; GENOTYPE; HEARING IMPAIRMENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; NEPHROTOXICITY; NEUROLOGY; NONHUMAN; ONTOGENY; ORGAN TRANSPLANTATION; OTOTOXICITY; PATHOPHYSIOLOGY; PEDIATRICS; PHARMACOGENOMICS; PHENOTYPE; REVIEW; RHEUMATIC DISEASE; SHORT STATURE; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; TPMT GENE;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENOME; GENOMICS; HUMANS; PEDIATRICS; PHARMACOGENETICS;

EID: 84893441052     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.193     Document Type: Review

References (147)

1. Leeder JS. Developmental and pediatric pharmacogenomics. Pharmacogenomics 4(3), 331-341 (2003). (Pubitemid 36546613)
2. Wang L. Pharmacogenomics: a systems approach. Wiley. Interdiscip. Rev. Syst. Biol. Med. 2(1), 3-22 (2010).
3. Hawcutt DB, Thompson B, Smyth RL, Pirmohamed M. Paediatric pharmacogenomics: an overview. Arch. Dis. Child. 98(3), 232-237 (2013). • Recent comprehensive review that describes pharmacogenomic methodology in relation to pediatrics.
4. Hogarth S, Liddell K, Ling T, Melzer D, Sanderson S, Zimmern R. Regulating pharmacogenomics: an overview of developments in various countries and industry response to regulatory initiatives. A report for Health Canada, Cambridge, ON, Canada (2006).
5. Gluckman PD, Hanson MA. Evolution, development and timing of puberty. Trends Endocrinol. Metab. 17(1), 7-12 (2006). (Pubitemid 43031378)
6. Thompson JL, Nelson AJ. Middle childhood and modern human origins. Hum. Nat. 22(3), 249-280 (2011).
7. Stevens A, Hanson D, Whatmore A, Destenaves B, Chatelain P, Clayton P. Human growth is associated with distinct patterns of gene expression in evolutionarily conserved networks. BMC Genomics 14(1), 547 (2013). • Identifies tissue-independent, age-related gene expression related to the stages of human development, a phenomenon that potentially underlies pediatric-specific effects in pharmacogenomics.
8. Russo R, Capasso M, Paolucci P, Iolascon A. Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives. Eur. J. Clin. Pharmacol. 67(Suppl. 1), 17-27 (2011).
9. Finkielstein GP, Forcinito P, Lui JC et al. An extensive genetic program occurring during postnatal growth in multiple tissues. Endocrinology 150(4), 1791-1800 (2009).
10. Rezvani G, Lui JC, Barnes KM, Baron J. A set of imprinted genes required for normal body growth also promotes growth of rhabdomyosarcoma cells. Pediatr. Res. 71(1), 32-38 (2012).
11. Lango AH, Estrada K, Lettre G et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467(7317), 832-838 (2010). • Identifies key SNPs that affect human height, maps these to growth-related biological pathways, and therefore identifies a genomic developmental background to pharmacogenomics.
12. Karlberg J, Kwan CW, Gelander L, Bertsson- Wikland K. Pubertal growth assessment. Horm. Res. 60(Suppl. 1), S27-S35 (2003).
13. Bogin B. Evolutionary perspective on human growth. Annu. Rev. Anthropol. 28, 109-153 (1999). • Discusses in detail the evidence that supports the return to long bone growth that accompanies puberty as a specifically human event, and therefore highlights the pharmacogenomic relevance of genes involved with this process.
14. Ranke MB, Lindberg A, Mullis PE et al. Towards optimal treatment with growth hormone in short children and adolescents: evidence and theses. Horm. Res. Paediatr. 79(2), 51-67 (2013). • Recent review that highlights the importance of personalized medicine in pediatrics and demonstrates the relevance of prediction of response.
15. Ranke MB, Lindberg A, Chatelain P et al. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J. Clin. Endocrinol. Metab. 84(4), 1174-1183 (1999). (Pubitemid 30644371)
16. Galinkin JL, Demmer L, Yaster M. Genetics for the pediatric anesthesiologist: a primer on congenital malformations, pharmacogenetics, and proteomics. Anesth. Analg. 111(5), 1264-1274 (2010).
17. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat. Rev. Cancer 6(2), 117-129 (2006). (Pubitemid 43361544)
18. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277- 300 (2010).
19. Husain A, Loehle JA, Hein DW. Clinical pharmacogenetics in pediatric patients. Pharmacogenomics 8(10), 1403-1411 (2007). (Pubitemid 350167103)
20. Hartford CM , Dolan ME. Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics 8(9), 1159-1168 (2007). (Pubitemid 47578225)
21. Ross CJ, Visscher H, Rassekh SR et al. Pharmacogenomics of serious adverse drug reactions in pediatric oncology. J. Popul. Ther. Clin. Pharmacol. 18, e134-e151 (2011). • Relates ototoxicity to treatment in children; a clear example of pediatric pharmacogenomics.
22. Adam de Beaumais T, Jacqz-Aigrain E. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur. J. Clin. Pharmacol. 68(9), 1233-1242 (2012).
23. Zhou S. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr. Clin. Pharmacol. 1(1), 119-128 (2006).
24. Lennard L, Lilleyman JS, Van LJ, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336(8709), 225-229 (1990). (Pubitemid 20229068)
25. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126(8), 608-614 (1997). (Pubitemid 27172187)
26. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 343(8907), 1188-1190 (1994). (Pubitemid 24147553)
27. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14(4), 567-572 (2000). (Pubitemid 30195445)
28. Serpe L, Calvo PL, Muntoni E et al. Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity. Pharmacogenomics 10(11), 1753-1765 (2009).
29. Relling MV, Gardner EE, Sandborn WJ et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin. Pharmacol. Ther. 93(4), 324-325 (2013).
30. Ulrich CM, Yasui Y, Storb R et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98(1), 231-234 (2001).
31. De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur. J. Cancer 45(8), 1333-1351 (2009).
32. Toffoli G, De ME. Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics 9(9), 1195-1206 (2008).
33. Aplenc R, Thompson J, Han P et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res. 65(6), 2482-2487 (2005). (Pubitemid 40490161)
34. Lee YH, Song GG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin. Drug Investig. 30(2), 101-108 (2010).
35. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10(1), 111-113 (1995).
36. Spyridopoulou KP, Dimou NL, Hamodrakas SJ, Bagos PG. Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis. Pharmacogenet. Genomics 22(2), 117- 133 (2012).
37. Radtke S, Zolk O, Renner B et al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 121(26), 5145- 5153 (2013).
38. Ramsey LB, Bruun GH, Yang W et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 22(1), 1-8 (2012).
39. Chen ZS, Lee K, Walther S et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62(11), 3144-3150 (2002). (Pubitemid 34602407)
40. Donelli MG, Zucchetti M, Robatto A et al. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med. Pediatr. Oncol. 24(3), 154-159 (1995).
41. Ware RE, Despotovic JM, Mortier NA et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 118(18), 4985-4991 (2011).
42. Ross CJ, Katzov-Eckert H, Dube MP et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41(12), 1345-1349 (2009).
43. Shaw K, Amstutz U, Carleton BC. Using pharmacogenetics to understand adverse drug reactions in children. Paediatr. Child Health 16(9), 537-538 (2011).
44. Mukherjea D, Rybak LP. Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics 12(7), 1039-1050 (2011).
45. Riedemann L, Lanvers C, Deuster D et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J. 8(1), 23-28 (2008).
46. Choeyprasert W, Sawangpanich R, Lertsukprasert K et al. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms. J. Pediatr. Hematol. Oncol. 35(4), e138-e143 (2013).
47. Pussegoda K, Ross CJ, Visscher H et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin. Pharmacol. Ther. 94(2), 243-251 (2013).
48. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur. J. Cancer 40(16), 2445-2451 (2004). (Pubitemid 39424959)
49. Brown TR, Vijarnsorn C, Potts J, Milner R, Sandor GG, Fryer C. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study. Pediatr. Blood Cancer 60(5), 842-848 (2013).
50. Visscher H, Ross CJ, Rassekh SR et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol. 30(13), 1422-1428 (2012).
51. McGhee SA. How the practice of allergy shows the promise and challenge of personalized medicine. Mol. Genet. Metab. 104(1-2), 3-6 (2011).
52. Binia A, Kabesch M. Respiratory medicine - genetic base for allergy and asthma. Swiss. Med. Wkly 142, w13612 (2012).
53. Weiss ST. New approaches to personalized medicine for asthma: where are we? J. Allergy Clin. Immunol. 129(2), 327-334 (2012).
54. Portelli M, Sayers I. Genetic basis for personalized medicine in asthma. Expert Rev. Respir. Med. 6(2), 223-236 (2012).
55. Tse SM, Tantisira K, Weiss ST. The pharmacogenetics and pharmacogenomics of asthma therapy. Pharmacogenomics J. 11(6), 383-392 (2011).
56. Jones BL. The impact of pharmacogenetics in the treatment of allergic disease and asthma. Mo. Med. 108(5), 361-365 (2011).
57. Sayers I. A tailored approach to asthma management: Arg(16) holds the key? Clin. Sci. (Lond.) 124(8), 517-519 (2013).
58. Bleecker ER, Nelson HS, Kraft M et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am. J. Respir. Crit. Care Med. 181(7), 676-687 (2010).
59. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 370(9605), 2118-2125 (2007). (Pubitemid 350296302)
60. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 100(12), 3184-3188 (1997). (Pubitemid 28022857)
61. Stockmann C, Fassl B, Gaedigk R et al. Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control. J. Pediatr. 162(6), 1222-1227 (2013).
62. Tantisira KG, Lake S, Silverman ES et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. 13(13), 1353-1359 (2004). (Pubitemid 38961642)
63. Tantisira KG, Hwang ES, Raby BA et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc. Natl Acad. Sci. USA 101(52), 18099-18104 (2004). (Pubitemid 40054080)
64. Klotsman M, York TP, Pillai SG et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet. Genomics 17(3), 189-196 (2007). (Pubitemid 46668003)
65. Lima JJ, Zhang S, Grant A et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am. J. Respir. Crit. Care Med. 173(4), 379-385 (2006). (Pubitemid 43228324)
66. Asano K, Shiomi T, Hasegawa N et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 12(7), 565-570 (2002). (Pubitemid 35177087)
67. Becker ML. Pharmacogenomics in pediatric rheumatology. Curr. Opin. Rheumatol. 24(5), 541-547 (2012).
68. Becker ML. Optimization of pediatric rheumatology therapeutics. Clin. Pharmacol. Ther. 91(4), 597-606 (2012).
69. Mori M, Naruto T, Imagawa T et al. Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan. Mod. Rheumatol. 19(1), 1-11 (2009).
70. Schmeling H, Biber D, Heins S, Horneff G. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J. Rheumatol. 32(9), 1832-1836 (2005). (Pubitemid 41324827)
71. Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J. 13(3), 227-234 (2012).
72. van der Straaten RJ, Wessels JA, de Vries- Bouwstra JK et al. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics 8(2), 141-150 (2007).
73. Yanagimachi M, Naruto T, Hara T et al. Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. Br. J. Clin. Pharmacol. 71(2), 237-243 (2011).
74. Becker ML, Leeder JS. Developmental pharmacogenetics in pediatric rheumatology: utilizing a new paradigm to effectively treat patients with juvenile idiopathic arthritis with methotrexate. Hum. Genomics Proteomics 2010, 257120 (2010).
75. Moncrieffe H, Hinks A, Ursu S et al. Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype. Pharmacogenet. Genomics 20(11), 665-676 (2010).
76. Becker ML, van Haandel L, Gaedigk R et al. Red blood cell folate concentrations and polyglutamate distribution in juvenile arthritis: predictors of folate variability. Pharmacogenet. Genomics 22(4), 236-246 (2012).
77. Schonau E, Westermann F, Rauch F et al. A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency. Eur. J. Endocrinol. 144(1), 13-20 (2001). (Pubitemid 32126907)
78. Ranke MB, Lindberg A, Chatelain P et al. Predicting the response to recombinant human growth hormone in Turner syndrome: KIGS models. KIGS International Board. Kabi International Growth Study. Acta Paediatr. Suppl. 88(433), 122-125 (1999). (Pubitemid 30007349)
79. Ranke MB, Lindberg A, Chatelain P et al. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study. J. Clin. Endocrinol. Metab. 85(11), 4212-4218 (2000). (Pubitemid 32055375)
80. Ranke MB, Lindberg A. The basis for optimising growth with growth hormone usage in children with idiopathic short stature: analysis of data from KIGS (Pfizer International Growth Study Database). Horm. Res. Paediatr. 76(Suppl. 3), S48-S50 (2011).
81. Ranke MB, Lindberg A. Prediction models for short children born small for gestational age (SGA) covering the total growth phase. Analyses based on data from KIGS (Pfizer International Growth Database). BMC Med. Inform. Decis. Mak. 11, 38 (2011).
82. Renehan AG, Solomon M, Zwahlen M et al. Growth hormone receptor polymorphism and growth hormone therapy response in children: a bayesian meta-analysis. Am. J. Epidemiol. 175(9), 867-877 (2012). • Meta-analysis of studies that clarifies the relationship of the d3 growth hormone receptor polymorphism to therapy; demonstrates that only a limited amount of the variation to treatment is explained by this frequent polymorphism, and therefore implies that other pharmacogenomic events may be relevant.
83. Wassenaar MJ, Dekkers OM, Pereira AM et al. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 94(10), 3721-3730 (2009).
84. Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat. Genet. 36(7), 720-724 (2004). (Pubitemid 38886633)
85. Binder G, Baur F, Schweizer R, Ranke MB. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J. Clin. Endocrinol. Metab. 91(2), 659-664 (2006). (Pubitemid 43236940)
86. Binder G, Trebar B, Baur F, Schweizer R, Ranke MB. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome. Clin. Endocrinol. (Oxf.) 68(4), 567-572 (2008). (Pubitemid 351388712)
87. Dorr HG, Bettendorf M, Hauffa BP et al. Different relationships between the first 2 years on growth hormone treatment and the d3-growth hormone receptor polymorphism in short small-for-gestational-age (SGA) children. Clin. Endocrinol. (Oxf.) 75(5), 656-660 (2011).
88. Pilecka I, Whatmore A, Hooft van HR, Destenaves B, Clayton P. Growth hormone signalling: sprouting links between pathways, human genetics and therapeutic options. Trends Endocrinol. Metab. 18(1), 12-18 (2007). (Pubitemid 46001593)
89. Stevens A, Clayton P, Tato L et al. Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome. Pharmacogenomics J. doi:10.1038/tpj.2013.14 (2013) (Epub ahead of print). • One of the first studies to integrate genetic and transcriptomic data to investigate pediatric pharmacogenomics.
90. Clayton PE, Chatelain P, Tato L et al. A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndrome. Eur. J. Endocrinol. 169, 277-289 (2013).
91. Clayton P, Bonnemaire M, Dutailly P et al. Characterizing short stature by insulin-like growth factor axis status and genetic associations: results from the prospective, cross-sectional, epidemiogenetic EPIGROW study. J. Clin. Endocrinol. Metab. 98(6), E1122-E1130 (2013).
92. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J. Am. Acad. Child Adolesc. Psychiatry 35(4), 409-432 (1996). (Pubitemid 126418605)
93. Froehlich TE, McGough JJ, Stein MA. Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs 24(2), 99-117 (2010).
94. Patel BD, Barzman DH. Pharmacology and pharmacogenetics of pediatric ADHD with associated aggression: a review. Psychiatr. Q. doi:0.1007/s11126-013-9253- 7 (2013) (Epub ahead of print).
95. Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J. Am. Acad. Child Adolesc. Psychiatry 38(12), 1474-1477 (1999).
96. Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH. Dopamine transporter gene and response to methylphenidate in attention-deficit/ hyperactivity disorder. Pharmacogenetics 12(6), 497-499 (2002). (Pubitemid 34913533)
97. Kirley A, Lowe N, Hawi Z et al. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 121B(1), 50-54 (2003). (Pubitemid 37064030)
98. Urban KR, Waterhouse BD, Gao WJ. Distinct age-dependent effects of methylphenidate on developing and adult prefrontal neurons. Biol. Psychiatry 72(10), 880-888 (2012).
99. Huang YS, Wang LJ, Chen CK. Long-term neurocognitive effects of methylphenidate in patients with attention deficit hyperactivity disorder, even at drug-free status. BMC Psychiatry 12, 194 (2012).
100. Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr. Drugs 15(2), 119-131 (2013).
101. Koukouritaki SB, Manro JR, Marsh SA et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J. Pharmacol. Exp. Ther. 308(3), 965-974 (2004). (Pubitemid 38263972)
102. Hagymasi K, Mullner K, Herszenyi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics 12(6), 873-888 (2011).
103. Kearns GL, Andersson T, James LP et al. Omeprazole disposition in children following single-dose administration. J. Clin. Pharmacol. 43(8), 840-848 (2003). (Pubitemid 36886104)
104. Kearns GL, Blumer J, Schexnayder S et al. Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. J. Clin. Pharmacol. 48(11), 1356-1365 (2008).
105. Zhao W, Fakhoury M, Jacqz-Aigrain E. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Ther. Drug Monit. 32(6), 688-699 (2010).
106. Cattaneo D, Vinks AA. Optimizing immunosuppressive drug dosing in pediatric renal transplantation. Part of a special series on Paediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharmacol. Res. 65(2), 163-167 (2012).
107. de Wildt SN, van Schaik RH, Soldin OP et al. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur. J. Clin. Pharmacol. 67(12), 1231-1241 (2011).
108. Fanta S, Niemi M, Jonsson S et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet. Genomics 18(2), 77-90 (2008).
109. Ferraresso M, Turolo S, Belinghieri M et al. The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients. Pediatr. Transplant. 16(6), 658-663 (2012).
110. Gijsen VM, Hesselink DA, Croes K, Koren G, de Wildt SN. Prevalence of renal dysfunction in tacrolimus-treated pediatric transplant recipients: a systematic review. Pediatr. Transplant. 17(3), 205-215 (2013).
111. Zhao W, Fakhoury M, Baudouin V et al. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur. J. Clin. Pharmacol. 69(2), 189-195 (2013).
112. Prytula AA, Bouts AH, Mathot RA et al. Intra-patient variability in tacrolimus trough concentrations and renal function decline in pediatric renal transplant recipients. Pediatr. Transplant. 16(6), 613-618 (2012).
113. Zhao W, Elie V, Roussey G et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin. Pharmacol. Ther. 86(6), 609-618 (2009).
114. Gijsen V, Mital S, van Schaik RH et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J. Heart Lung Transplant. 30(12), 1352-1359 (2011).
115. Gijsen VM, van Schaik RH, Elens L et al. CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics 14(9), 1027-1036 (2013).
116. Ansari M, Krajinovic M. Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation? Pharmacogenomics 10(11), 1729-1732 (2009).
117. McCune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting. Expert Opin. Drug Metab. Toxicol. 5(8), 957-969 (2009).
118. Meisel C, Gerloff T, Kirchheiner J et al. Implications of pharmacogenetics for individualizing drug treatment and for study design. J. Mol. Med. (Berl.) 81(3), 154-167 (2003). (Pubitemid 36470182)
119. Gallagher RM, Mason JR, Bird KA et al. Adverse drug reactions causing admission to a paediatric hospital. PLoS ONE 7(12), e50127 (2012).
120. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br. J. Clin. Pharmacol. 52(1), 77-83 (2001). (Pubitemid 32862772)
121. Easton KL, Chapman CB, Brien JA. Frequency and characteristics of hospital admissions associated with drug-related problems in paediatrics. Br. J. Clin. Pharmacol. 57(5), 611-615 (2004). (Pubitemid 38582181)
122. Gonzalez-Martin G, Caroca CM, Paris E. Adverse drug reactions (ADRs) in hospitalized pediatric patients. A prospective study. Int. J. Clin. Pharmacol. Ther. 36(10), 530-533 (1998). (Pubitemid 28468228)
123. Rawlins M, Thompson J. Pathogenesis of adverse drug reactions. In: Textbook of Adverse Drug Reactions. Davies D (Ed.). Oxford University Press, Oxford, UK (1977).
124. Wei CY, Lee MT, Chen YT. Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Hum. Mol. Genet. 21(R1), R58-R65 (2012).
125. Blumenfeld YJ, Reynolds-May MF, Altman RB, El-Sayed YY. Maternal-fetal and neonatal pharmacogenomics: a review of current literature. J. Perinatol. 30(9), 571-579 (2010).
126. Adjei AA, Gaedigk A, Simon SD, Weinshilboum RM, Leeder JS. Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res. A Clin. Mol. Teratol. 82(3), 155-165 (2008). (Pubitemid 351458137)
127. Kelly LE, Rieder M, van den Anker J et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics 129(5), e1343-e1347 (2012).
128. Shaw KD, Amstutz U, Jimenez-Mendez R, Ross CJ, Carleton BC. Suspected opioid overdose case resolved by CYP2D6 genotyping. Ther. Drug Monit. 34(2), 121-123 (2012).
129. Gaedigk A, Ndjountche L, Divakaran K et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin. Pharmacol. Ther. 81(2), 242-251 (2007). (Pubitemid 46178274)
130. Madadi P, Ross CJ, Hayden MR et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin. Pharmacol. Ther. 85(1), 31-35 (2009).
131. Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin. Pharmacol. Ther. 92(6), 757-765 (2012).
132. Nassif A, Bensussan A, Boumsell L et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114(5), 1209-1215 (2004). (Pubitemid 39469167)
133. McCormack M, Alfirevic A, Bourgeois S et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364(12), 1134-1143 (2011).
134. Ozeki T, Mushiroda T, Yowang A et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20(5), 1034-1041 (2011).
135. Shi YW, Min FL, Qin B et al. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502? Basic Clin. Pharmacol. Toxicol. 111(1), 58-64 (2012).
136. Zakrzewska JM, Ivanyi L. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10, 11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J. Allergy Clin. Immunol. 82(1), 110-115 (1988).
137. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J. Immunol. 155(1), 462-472 (1995).
138. Syn WK, Naisbitt DJ, Holt AP, Pirmohamed M, Mutimer DJ. Carbamazepine-induced acute liver failure as part of the DRESS syndrome. Int. J. Clin. Pract. 59(8), 988-991 (2005).
139. Hung CC, Huang HC, Gao YH et al. Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients. Pharmacogenomics 13(12), 1339-1349 (2012).
140. Twardowschy CA, Werneck LC, Scola RH, De PL, Silvado CE. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation. Arq. Neuropsiquiatr. 69(2A), 153-158 (2011).
141. Choi H, Pavelka N. When one and one gives more than two: challenges and opportunities of integrative omics. Front. Genet. 2, 105 (2011).
142. Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput. Biol. 3(4), e59 (2007).
143. Sun J, Zhao Z. A comparative study of cancer proteins in the human protein-protein interaction network. BMC Genomics 11(Suppl. 3), S5 (2010).
144. Laenen G, Thorrez L, Bornigen D, Moreau Y. Finding the targets of a drug by integration of gene expression data with a protein interaction network. Mol. Biosyst. 9(7), 1676-1685 (2013).
145. Iorio F, Isacchi A, di BD, Brunetti-Pierri N. Identification of small molecules enhancing autophagic function from drug network analysis. Autophagy 6(8), 1204-1205 (2010).
146. US FDA. Table of pharmacogenomic biomarkers in drug labels. www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm
147. US FDA. FDA Drug Safety Communication: Codeine use in certain children after tonsillectomy and/or adenoidectomy may lead to rare, but life-threatening adverse events or death. www.fda.gov/Drugs/DrugSafety/ucm313631. htm